fluconazole has been researched along with Adverse Drug Event in 18 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a single-centre, retrospective study of adult patients (≥18 years) with proven or probable coccidioidomycosis receiving long-term fluconazole therapy for an intended duration of ≥28 days." | 3.91 | Tolerability of long-term fluconazole therapy. ( Davis, MR; Donnelley, MA; Nguyen, MH; Thompson Iii, GR, 2019) |
| " Local irritation was the primary adverse event associated with terconazole, whereas systemic side effects were associated with fluconazole; however, these effects were minimal." | 2.80 | A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. ( Fan, S; Li, T; Liang, Y; Liu, X; Xu, H; Zhu, Y, 2015) |
| "Anidulafungin was effective, safe and well tolerated for the treatment of C/IC in selected groups of ICU patients." | 2.77 | Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. ( Auzinger, G; Borges Sá, M; Dimopoulos, G; Grigoras, I; Kantecki, M; Marček, T; Meersseman, W; Menichetti, F; Miller, PJ; Montravers, P; Pachl, J; Paiva, JA; Ruhnke, M; Sganga, G, 2012) |
| "As a mainstay of treatment for acute lymphoblastic leukemia (ALL), vincristine's side effect profile is well known." | 1.91 | Vincristine Side Effects With Concomitant Fluconazole Use During Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. ( Beck, J; Cave, C; Ford, J; High, R; Ramirez, R; Raulji, C, 2023) |
| "Neurologic adverse effects of triazole antifungal compounds used for the treatment of systemic and deep mycoses are relatively rare." | 1.62 | Acute fluconazole toxicity: a case presenting with protean manifestations including systemic and neurologic symptoms. ( Ergene, U; Eşkut, N; Gedizlioğlu, M; Özlü, C; Ünal, O, 2021) |
| "Rhabdomyolysis is a serious complication of statin treatment." | 1.46 | Weakness and pain in arms and legs · dark urine · history of vertebral osteomyelitis · Dx? ( Brateanu, A; Charokopos, A; Muhammad, T; Surbhi, S, 2017) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "Fluconazole resistance was observed among 26% of all Candida isolates and 17." | 1.37 | An observational study on the epidemiological and mycological profile of Candidemia in ICU patients. ( Biswas, D; Gupta, A; Jindal, P; Kotwal, A; Sharma, JP, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Mohamed, MS | 1 |
| Kamel, MM | 1 |
| Kassem, EM | 1 |
| Abotaleb, N | 1 |
| Abd El-Moez, SI | 1 |
| Ahmed, MF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Imatoh, T | 1 |
| Matsumoto, T | 1 |
| Haramaki, Y | 1 |
| Migita, K | 1 |
| Cave, C | 1 |
| Ramirez, R | 1 |
| High, R | 1 |
| Ford, J | 1 |
| Raulji, C | 1 |
| Beck, J | 1 |
| Eşkut, N | 1 |
| Gedizlioğlu, M | 1 |
| Ünal, O | 1 |
| Özlü, C | 1 |
| Ergene, U | 1 |
| Johnston, JP | 1 |
| Cohen, EA | 1 |
| Casal, GH | 1 |
| Asch, WS | 1 |
| Reardon, DP | 1 |
| Davis, MR | 1 |
| Nguyen, MH | 1 |
| Donnelley, MA | 1 |
| Thompson Iii, GR | 1 |
| Nyirjesy, P | 1 |
| Alessio, C | 1 |
| Jandourek, A | 1 |
| Lee, JD | 1 |
| Sandison, T | 1 |
| Sobel, JD | 1 |
| Döring, M | 1 |
| Eikemeier, M | 1 |
| Cabanillas Stanchi, KM | 1 |
| Hartmann, U | 1 |
| Ebinger, M | 1 |
| Schwarze, CP | 1 |
| Schulz, A | 1 |
| Handgretinger, R | 1 |
| Müller, I | 1 |
| Li, T | 1 |
| Zhu, Y | 1 |
| Fan, S | 1 |
| Liu, X | 1 |
| Xu, H | 1 |
| Liang, Y | 1 |
| Charokopos, A | 1 |
| Muhammad, T | 1 |
| Surbhi, S | 1 |
| Brateanu, A | 1 |
| Kotwal, A | 1 |
| Biswas, D | 1 |
| Sharma, JP | 1 |
| Gupta, A | 1 |
| Jindal, P | 1 |
| Ruhnke, M | 1 |
| Paiva, JA | 1 |
| Meersseman, W | 1 |
| Pachl, J | 1 |
| Grigoras, I | 1 |
| Sganga, G | 1 |
| Menichetti, F | 1 |
| Montravers, P | 1 |
| Auzinger, G | 1 |
| Dimopoulos, G | 1 |
| Borges Sá, M | 1 |
| Miller, PJ | 1 |
| Marček, T | 1 |
| Kantecki, M | 1 |
| Meier, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe[NCT02180100] | Phase 4 | 140 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Efflux Pump Mediated Azole Resistance in Candida Albicans Among Neutropenic Patients With Haematological Malignancies[NCT03659162] | 100 participants (Anticipated) | Observational | 2019-02-17 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Based on candida culture (NCT02180100)
Timeframe: Between day 7-14 after treatment, an average of 10 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Terconazole Vaginal Suppository | 46 |
| Fluconazole | 47 |
Based on Candida culture (NCT02180100)
Timeframe: Between day 28-35 after treatment, an average of 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Terconazole Vaginal Suppository | 36 |
| Fluconazole | 35 |
3 trials available for fluconazole and Adverse Drug Event
| Article | Year |
|---|---|
CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial.
Topics: Administration, Oral; Administration, Topical; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; | 2019 |
A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Case-Control | 2015 |
Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidiasis, Invasive; Cr | 2012 |
15 other studies available for fluconazole and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Novel 6,8-dibromo-4(3H)quinazolinone derivatives of anti-bacterial and anti-fungal activities.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Drug Design; Drug-Related Side Effects and Adver | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Impact of Concomitant Use of Azoles on Bortezomib-related Adverse Drug Reactions Using JADER.
Topics: Azoles; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Fluconazole; Humans; Itraconazo | 2023 |
Vincristine Side Effects With Concomitant Fluconazole Use During Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.
Topics: Antifungal Agents; Child; Drug-Related Side Effects and Adverse Reactions; Fluconazole; Humans; Hypo | 2023 |
Acute fluconazole toxicity: a case presenting with protean manifestations including systemic and neurologic symptoms.
Topics: Acute Kidney Injury; Antifungal Agents; Confusion; Drug-Related Side Effects and Adverse Reactions; | 2021 |
Impact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant.
Topics: Antifungal Agents; Azoles; Drug-Related Side Effects and Adverse Reactions; Fluconazole; Graft Rejec | 2022 |
Tolerability of long-term fluconazole therapy.
Topics: Adult; Antifungal Agents; Coccidioidomycosis; Drug-Related Side Effects and Adverse Reactions; Femal | 2019 |
Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
Topics: Adolescent; Antifungal Agents; Chemoprevention; Child; Child, Preschool; Cohort Studies; Drug-Relate | 2015 |
Weakness and pain in arms and legs · dark urine · history of vertebral osteomyelitis · Dx?
Topics: Adult; Arm; Cytochrome P-450 CYP3A Inhibitors; Diagnosis, Differential; Drug Interactions; Drug-Rela | 2017 |
An observational study on the epidemiological and mycological profile of Candidemia in ICU patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Candida; Candidemia; Child; Child, Preschool; Drug Resistance, F | 2011 |
Results of drug trials can mystify doctors through omission: some professional groups demand public listing of all test outcomes.
Topics: Adult; Child; Clinical Trials as Topic; Databases, Factual; Disclosure; Drug Approval; Drug Industry | 2004 |